Zota Health Care LImited (ZOTA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Zota Health Care LImited stock ₹1,969, price ₹1,231, upside +59.9%, quality 29 out of 100. Rating: strongly undervalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers generic drugs, health supplements, over-the-counter products, wellness and ayurvedic products, and nutraceutical products.
Show moreShow less
It provides various medicines for chronic ailments, such as diabetes, cardiac, and thyroid disorders. The company operates its retail stores under the DAVAINDIA name. Zota Health Care Limited was founded in 1995 and is headquartered in Surat, India.
Stock analysis
Zota Health Care LImited (ZOTA) currently trades at ₹1,231, while our model-based Fair Value estimate is ₹1,969, implying the stock looks roughly 37% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: ₹460.58 (bear) to ₹3,478 (bull), the price of ₹1,231 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Zota Health Care LImited reported revenue of ₹5.4B in FY2026 versus ₹1.3B in FY2022, a compound +42.3%/yr. Reported net income was −₹739M in FY2026.
Key figures
Market cap ₹42.7B (≈ $455M) Small · P/S ratio 7.58 · EPS (TTM) ₹−31.41 · Dividend yield 0.1% · Net margin −17.0% · Return on equity −16.1% · Return on assets (EBIT) −3.4% (5-year average) · Operating margin −22.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 27% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 60%, ZOTA screens cheaper than that median.
Fair Value models
Bear₹460.58Fair Value ₹1,969Bull₹3,478
Price ₹1,231 · Upside +59.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA₹541.86₹2,316₹4,09160
NCAV (Graham)₹354.29₹536.17₹670.6954
All 2 models by family
Multiples
EV/EBITDA₹541.86₹2,316₹4,09160
Asset-Based
NCAV (Graham)₹354.29₹536.17₹670.6954
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+83.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.2%
Start year 2021 (pandemic). Over 10 years: +23.6% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2.3% (2021) → −11.9% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Compare Zota Health Care LImited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score29 · Bottom 25%
Fair Value upside+59.9% · Top 25%
Profitability
Return on assets−6.5% · Above median
Net margin (12 months)−17.0% · Below median
Operating margin (12 months)−22.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)67.6% · Top 25%
Dividend yield (12 months)0.1% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zota Health Care LImited Fair Value". https://www.fairvalue-calculator.com/stock/ZOTA
Frequently asked questions
Is Zota Health Care LImited (ZOTA) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of ₹1,969 versus a price of ₹1,231, about +60% upside (undervalued).
What is the fair value of ZOTA?
Our model-based fair value for Zota Health Care LImited is ₹1,969 (as of Nov 4, 2026), built from audited fundamentals. The current price: ₹1,231.
What is the quality score of ZOTA?
Zota Health Care LImited has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zota Health Care LImited (ZOTA)?
Our model-based price target is the fair value of ₹1,969 (as of Nov 4, 2026) from 2 valuation models. Cautious scenario ₹460.58, optimistic scenario ₹3,478. It is a calculation from audited fundamentals, not an analyst target.
What is the Zota Health Care LImited stock forecast for 2026?
Our models put fair value at ₹1,969, about +60% upside versus a price of ₹1,231 (undervalued). Cautious scenario ₹460.58, optimistic scenario ₹3,478. The calculation is refreshed regularly with new filings.
What is the revenue of Zota Health Care LImited (ZOTA)?
Zota Health Care LImited reported trailing-twelve-month revenue of about ₹6.1B (latest available figure, as of Nov 4, 2026).
Does Zota Health Care LImited pay a dividend?
Zota Health Care LImited currently shows a dividend yield of 0.08% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Zota Health Care LImited (ZOTA) and when is the ex-dividend date?
Zota Health Care LImited pays a dividend of ₹1.00 per share a year, a dividend yield of 0.1%. The last ex-dividend date was Sep 21, 2026. A dividend has been paid every year since at least 2017. Our assessment: Token dividend. At a yield of 0.1% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.1% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Zota Health Care LImited (ZOTA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zota Health Care LImited it is ₹1,969 per share (as of Nov 4, 2026), against a price of ₹1,231. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Zota Health Care LImited stock overvalued or undervalued in 2026?
As of Nov 4, 2026, ZOTA trades below its calculated fair value: price ₹1,231, fair value ₹1,969, a gap of about +60% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZOTA?
No. The price is what the market pays today (₹1,231); the fair value is what the company's own numbers justify (₹1,969). For Zota Health Care LImited the two are ₹737.63 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zota Health Care LImited worth?
The market values Zota Health Care LImited at about ₹42.7B (market capitalisation, as of Nov 4, 2026). Per share that is ₹1,231; our models calculate a fair value of ₹1,969 per share.
What do the bullish and bearish scenarios say about ZOTA?
Our models span a range for Zota Health Care LImited: cautious scenario ₹460.58, base ₹1,969, optimistic ₹3,478 per share (as of Nov 4, 2026, price ₹1,231). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zota Health Care LImited (ZOTA)?
Balance-sheet figures for Zota Health Care LImited (as of Nov 4, 2026): return on equity −16.1%, debt of 0.01 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is ZOTA from its 52-week high?
Zota Health Care LImited trades at ₹1,231, about 27% below its 52-week high of ₹1,686 and 20% above the low of ₹1,027 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,969 is for.
Which stocks are comparable to Zota Health Care LImited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zota Health Care LImited stock attractive at the current price?
The data as of Nov 4, 2026: price ₹1,231, calculated fair value ₹1,969 (+60%), Quality Score 29/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZOTA calculated?
We run Zota Health Care LImited through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of ₹1,969 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Zota Health Care LImited currently trades 37% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zota Health Care LImited (ZOTA)?
The closing price on Nov 6, 2026 was ₹1,231. Our model-based fair value is ₹1,969, about +60% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zota Health Care LImited right now?
The large discount to fair value meets weak quality (29/100). That raises the risk this is a value trap rather than a bargain. The model range is unusually wide (₹460.58 to ₹3,478). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Zota Health Care LImited
How large is the market capitalisation of Zota Health Care LImited (ZOTA)?
The market capitalisation of Zota Health Care LImited is ₹42.7B (≈ $455M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zota Health Care LImited (ZOTA)?
The price-to-sales ratio of Zota Health Care LImited is 7.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zota Health Care LImited (ZOTA)?
Earnings per share at Zota Health Care LImited are ₹−31.41. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zota Health Care LImited (ZOTA)?
The dividend yield of Zota Health Care LImited is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zota Health Care LImited (ZOTA)?
The net margin of Zota Health Care LImited is −17.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zota Health Care LImited (ZOTA)?
The return on equity (ROE) of Zota Health Care LImited is −16.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zota Health Care LImited (ZOTA)?
On an EBIT basis the return on assets of Zota Health Care LImited is −3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zota Health Care LImited (ZOTA)?
The operating margin of Zota Health Care LImited is −22.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zota Health Care LImited (ZOTA)?
Revenue at Zota Health Care LImited is growing +67.6% versus a year earlier (3y avg +56.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zota Health Care LImited (ZOTA)?
Earnings per share at Zota Health Care LImited are growing −72.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zota Health Care LImited (ZOTA) generate?
The free cash flow of Zota Health Care LImited is −₹1.9B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zota Health Care LImited (ZOTA) carry?
The net debt of Zota Health Care LImited is ₹1.7B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Zota Health Care LImited in the live analysis
One click puts Zota Health Care LImited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026